I’m going to have a look tomorrow, but how do you go about constructing such a thing. If you simply picked the top 10, then you might find you are restricted to a certain sector, so I would think this should be loosely based on an all world index fund.
I do like the principle, rather than ‘unloved’, essentially you are adding money where there is value.
constructing something like this would require us to define ‘unloved’ a bit more presicely, personally don’t like buying funds other than low costs ETFs but would be interesting in building and maintaining a couple of unloved stocks pies fore all the unloved sectors.
There are a couple options. The Morningstar article writes that it picks the most unloved stock from three different categories - defined as the fund with the most outflows if I understand correct.
Now we could mimic these funds, but that would rely on having to monitor its portfolio statements from time to time.
My other thought, was could it be repeated with Investment Trusts, hence the AIC link. That way we could set something up, regularly invest, and only need to review the choice of three every year or so. We shouldn’t need to look at the flows, but could use the discount/premium instead, and the AIC sector.
I would say of my holdings ones some might class unloved/overlooked/undervalued are:
BP (my oil/old energy play) HSBC (my UK bank play, with asian lean) ULVR (just solid stock seemingly unloved) GSK (When this splits companies could be worth a lot more in coming years, in mean time about a 6% div on current price)
And in my portfolio they play this role, well sort of. So BP & HSBC are partk of my unloved/rebound value plays (along with TW) and ULVR and GSK are really 2 of my 5 core dividend plays but I feel both unloved right now.
Arguably the ones I list are unloved for good reasons, however I think ULVR is a great value play at this price, 3%+ dividend, still growing (small amount) dividend each year and has such a strong cash flow.
This could work.
I tend to look at Earned Vale / EVITDA as EV includes market capitalisation and debt. Not to say that it is the way to go though. Also note that I do not use it for financial companies.
I have also been looking at Cyclically Adjsted Price to Earnings Ratio (CAPE) to see which markets are “cheaper”, which I guess is also “unloved”. From the link below, some examples are Russia, Poland, Czech Repblic, Jordan, Oman, Colombia and Turkey. A bit “less cheap” we can find Austria, the UK and Spain.
I have not found a ETF for Austria, so I was thinking of looking into some of its stocks once they get added It is one of the most likely exchanges to be added this year. (See David’s post below)
In terms of the countries above, from the first batch there are ETFs and Stocks for Russia on T212. There are also iShares ETFs for Turkey and Poland.
I couldn’t find any for Austria and the Czech Republic which I think are currently probably more stable countries and hence would be more reasonable to invest into a Country ETF without knowing much… What are your thoughts?
I guess you could even combine “cheap country stock market” with “cheap fund” and look into investment companies investing in this at a discount. Examples:
The debt of financials are a bit harder to evaluate, I have not found a good way of evaluating themt apart from maybe Price to Earnings Ratio and Price to Book.
I don’t know of a way to really evaluate their “debt”. For example I have found that the EV/EBITDA ratio that I use for other stocks tends to be useless with financial companies.
Another way of targetting “unloved stocks” would be to buy an ETF tracking a “Value” or “Value weighted”.
For example on T212 we have the SPDR MSCI Europe Small Cap Value Weighted and SPDR MSCI USA Small Cap Value Weighted, both with a TER of 0.30%. Based on the idea that “unloved stocks” are those with low valuations (and high earnings compared to their price).
The index has the following methodology taken from an MSCI document linked below - a bit like a factsheet -, I seem to remember that MSCI had a more detailed document available but I have not been able to find it now.
So as you can see, it considers sales, book value, earnings and cash earnings.
Many of you are likely to know this better than me, but as a brief summary research from Fama and French is meant to have shown that different factors have different long-term returns, with “Small Cap” and “profitability” being one of the ones with the largest long-term outperformance, potentially because of the larger risks and less liquidity in the case of small caps as well as the long-term correlation between earnings and share price in the case of the profitability factor, which is then transformed into the “value” aspect.
There are quite a few articles online about this, however the first source where I came accross the research was on Ben Felix’s videos on Youtube (hopefully this is the correct video):
Important to consider that those are the products that he suggests to some of his clients, so he is likely to be significantly biased.
Hello. I own GSK and ULVR. I’m curious if you are thinking of buying either at moment. I’m currently down 20% on GSK but looking to buy some more Monday. It’s one of my stocks which I’m looking to hold long term.
I added to ULVR recently, last time was at 3850p ish, currently sitting below that so I will keep an eye and add more potentially. GSK I am not adding too right now purely because it is already a large enough chunk of my portfolio, but as that comes down as I add to some other positions if the price is still here or under 1300 I would happily buy more.
In short ULVR and GSK would be sure fire significant buys for me if they were not already significant positions. I own them as I think great businesses long term and also they make up a dividend pie I have of GSK, JNJ, ULVR, DGE, although at these prices GSK/ULVR would make it into my ‘value pie’ (where I buy undervalued stocks) as so undervalued IMO.
If I had to load up on just 1 of the 2, ULVR might pip it as I think (rightly or wrongly) its the sort of company that at these prices wouldn’t be surprised someone making big purchases of it like a Berkshire Hathaway type company (probably not them as they tried to buy outright and since havent shown any other interest as far as im aware). ULVR also now has a strong dividend of 4% which is a big threshold to buy I would argue for a company that is growing this dividend too.
Interesting pop in price for GSK on an activist fund buying into GSK heavily. Looks to be quickly selling off some of those gains but lets see if this is short lived or a move to start trending up this year. My dividend reinvestment was done at 1290p price so just letting that badboy compound, not adding new funds to it now.
Activist hedge fund Elliott Management has built a multibillion-pound stake in UK drugmaker GSK, setting up a potential battle over the company’s future after it underperformed peers and lagged in the race to develop a Covid-19 vaccine.
The stake taken by Elliott, the $42bn fund known for its campaigns at BHP, SoftBank and Whitbread, was confirmed by people with knowledge of the investment and is a “significant” position, according to one of them.
my position average is still a bit above the current price as I got in at a price I was already satisfied with for the Dividend and preferred new funds going elsewhere. Think it’s a good sign its price will start to track up again as more people start to reconsider opening a position.